GBGrazyna Bednarek-Tupikowska

Grazyna Bednarek-Tupikowska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Grazyna Bednarek-Tupikowska has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Interdisciplinary aspects of primary hyperparathyroidism: symptomatology in a series of 100 cases (single-centre experience)

    by Anna Jodkowska, Krzysztof Tupikowski, Jadwiga Szymczak, Anna Bohdanowicz-Pawlak, Marek Bolanowski, Grazyna Bednarek-Tupikowska

    Introduction: Primary hyperparathyroidism (PHPT) is a common endocrine disorder. Beside renal and skeletal complications, it has a wide variety of nonspecific symptoms from other organs that may mimic other diseases and delay the diagnosis. Nowadays PHPT evolves to less-symptomatic. Aim: The aim is to revise symptomatology profile of PHPT in a single region of Poland; and to help early PHPT diagnosis – encouraging interdisciplinary contact between medical professionals. Methods: We analyzed retrospectively data of 100 patients with PHPT diagnosed in our centre during the past decade: 94 women and six men, aged averagely 57.1 years (S.D. 13.7 years). We evaluated biochemical conditions (hypocalcaemia, hypercalciuria, hypophosphatemia, and PTH level elevation) and clinical manifestations: renal, skeletal, cardiovascular, gastrointestinal, and asymptomatic. Results: Renal symptoms were present in 55%, as isolated symptoms in 14%. In the course of unrecognized disease seven cases of lithotripsy, seven operative lithotomies, two nephrectomies were performed. Osteoporosis/osteopenia was present in 66 and 10% respectively, and in 35% as the only PHPT presentation. In 16% fragility fractures, in 10% brown tumors were present. Fifty-five percent of PHPT patients were hypertensive and 21% ischemic heart disease positive. Gastrointestinal symptoms were present in 52%, in three cases (5.8% of 52), pancreatitis was documented. The incidental diagnosis of PHPT in asymptomatic patients was held in 15%. Mean serum Ca was 2.87 mmol/l (S.D.: 0.36), mean urine Ca was 15.97 mEq/24 h (S.D. 7.89), mean serum iPTH was: 324.11 pg/ml (S.D. 425.21). The duration time from any symptom appearance to the diagnosis varied between immediate diagnosis (19%), 1–10 years (46%), and >10 years (35%). Conclusion: PHPT is still diagnosed too late, usually after a long time of untreated symptomatic disease. There is a need of active PHPT search. Multidisciplinary cooperation between specialists on the diagnostic level brings hope to avoid late complications of unrecognized disease.

  • VDR gene polymorphisms in Alzheimer's disease: pilot study

    by Lukasz Laczmanski, Marta Jakubik, Joanna Rymaszewska, Grazyna Bednarek-Tupikowska, Felicja Lwow, Natalia Sloka, Andrzej Milewicz

    Aggravation of the symptoms of Alzheimer’s disease may also underlie the functioning of receptors associated with calcium and vitamin D. Therefore, it seems reasonable to study the correlation of polymorphisms of vitamin D receptor (VDR) and calcium receptor (CASR) with symptoms of AD. Alzheimer’s disease, vitamin D deficiency and osteoporosis often coexist in the patient. Research suggests that vitamin D deficiency is much more frequent in the patients with AD. Expression of VDR gene occurs in a neuronal and a glial cells. VDR belongs to the nuclear receptor superfamily and acts as a ligand activated transcription factor. During the project it was selected a 40 patients and a group of 40 healthy volunteers. There are many polymorphisms in the VDR gene. In the present work we focused on assessing the prevalence of four of them relating to the regulation of expression of this gene: TaqI, ApaI, FokI and BsmI. Distribution of all polymorphisms were obtained according to Hardy–Weinberg low (ApaI: χ2=2.54, P=0.1111, TaqI: χ2=1.21, P=0.2412, BsmI: χ2=0.57, P=0.4490, and FokI: χ2=1.23, P=0.2680). We didn’t observe any significant differences in the distribution of individual genotypes of the VDR polymorphisms in patients with Alzheimer’s disease compared to control group. Project requires further research with a larger group of patients and control group. The project was funded by the National Science Centre, grant number. UMO-2011/01/B/NZ7/00656.

    • 1 January 2014
      • Vol. 36  (211) , 42-4

    [Thyroid dysfunction in patients treated with tyrosine kinase inhibitors].

    by Justyna Przytulska, Krzysztof Tupikowski, Grazyna Bednarek-Tupikowska

    Tyrosine kinase Inhibitors are relatively new drugs used for treatment of several malignancies. The treatment is generally well tolerated, incidence of side effects of significant intensity is low. Hypothyroidism is a frequent complication, the mechanism and guidelines on endocrine treatment remain controversial. Observations indicate that hypothyroidism during treatment is correlated with higher probability of better response to treatment. Further research is necessary to establish guidelines on thyroid function tests and indications for treatment of hypothyroidism.

    • 5 March 2013
      • Vol. 21  (6) , 821-9

    Genetic aspects of pheochromocytoma.

    by Katarzyna Kolačkov, Krzysztof Tupikowski, Grażyna Bednarek-Tupikowska

    Pheochromocytomas are derived from chromaffin cells of the adrenal medulla which synthesize and secrete catecholamines, thus affecting the cardiovascular system and metabolic processes. Pheochromocytoma is a tumor of the following multicarcinoma hereditary syndromes: type 2 multiple endocrine neoplasia, von Hippel-Lindau disease, type 1 neurofibromatosis and the pheochromocytomas/paragangliomas syndrome. Pheochromocytomas are relatively rare, and because of non-specific manifestation of these tumors and the possible lack of signs and symptoms for extended periods of time, the diagnosis may be delayed, which may, in turn, lead to death. Pheochromocytomas may occur sporadically. However, due to the frequent incidence of hereditary forms of these cancers, the presymptomatic genetic testing of family members with a positive family history is indicated, thus allowing for selecting people with higher risk of cancer. Early detection of the syndrome and the coexisting tumors (which may be malignant) may lead to a correct diagnosis, regular surveillance, preventive examinations and implementation of appropriate early treatment. Recent examinations have shown significant involvement of RET, VHL, NF1, SDHB and SDHD as well as the newly discovered KIF1Bβ, TMEM127 and MAX genes in pathogenesis of these tumors. The microarray-gene expression studies, based on the analysis of cellular pathways, have revealed two distinct clusters indicating two different routes of tumorgenesis. The genotype-phenotype correlations are still being studied and future research can give us clearer information about the function of these genes, which may prove crucial from the clinical point of view.


    • 1 January 2013
      • Vol. 34  (2) , 107-10

    Primary hyperparathyroidism presenting as a giant cell tumor of the jaws.

    by Wojciech Pawlak, Anna Bohdanowicz-Pawlak, Marek Bolanowski, Jadwiga Szymczak, Grazyna Bednarek-Tupikowska, Klaudiusz Luczak

    Giant cell tumors of the maxillofacial skeleton are uncommon, they are usually late manifestation of primary hyperparathyroidism. A series of five clinical cases in four women and one man presenting as the giant cell lesions in the maxilla and/or mandible are discussed. Biopsy of the lesions, biochemical and hormonal analyses, densitometry and parathyroid scintigraphy were carried out. Biopsy of the lesions showed giant cell tumor of bone. The medical history and laboratory analyses showed primary hyperparathyroidism. Bone density loss was documented and scintigraphy revealed the presence of parathyroid adenomas in four cases. Surgical treatment of hyperparathyroidism, and in the second step - after 6-12 months - the subsequent excision of residual brown tumors in all cases was performed. One should have in mind that osteolytic bone lesions may be due to metabolic disease of the bone. Accurate diagnosis enabling the proper treatment should be carried out, avoiding unnecessary harm to the patients.


    • 1 January 2013
      • Vol. 64  (3) , 186-91

    Subclinical Cushing's syndrome in adrenal incidentalomas--possible metabolic consequences.

    by Anna Bohdanowicz-Pawlak, Jadwiga Szymczak, Ewa Waszczuk, Marek Bolanowski, Grażyna Bednarek-Tupikowska

    The presence of subclinical Cushing's syndrome (SCS) and some features of the metabolic syndrome were evaluated in adrenal incidentaloma patients. 165 patients were studied. Plasma cortisol, ACTH, DHEA-S, 17-OH-P, aldosterone, renin activity and 24-h urinary methoxycatecholamines were measured. Fasting concentrations of glucose, insulin, triglycerides, T-chol., HDL-chol. and LDL-chol. were determined and the FIRI and QUICKI indices were calculated. Blood pressure, WHR and BMI were determined in all patients. Forty healthy volunteers were the controls. 133 patients had unchanged endocrine function, 32 demonstrated hormonal disturbances without clinical symptoms (in 26 nonclinical hypercortisolism). The WHR and blood pressure in the SCS group were significantly higher than in the patients with nonfunctioning adenoma (NA). T-chol and LDL-chol were significantly higher, but HDL-chol was significantly lower, in the SCS than in the NA patients. Fasting insulin level was significantly higher in the SCS than in the NA patients and controls, while fasting glucose level was comparable. QUICKI was significantly lower in the SCS and NA patients than in the controls, while FIRI was significantly higher in the SCS group. In incidentaloma patients, hormonal function of the adrenal gland should be estimated because some of them present subclinical hyperfunction. These patients frequently display features of metabolic syndrome such as insulin resistance, hypertension, high triglycerides, T-chol and LDL-chol levels. Subtle autonomous cortisol secretion may be the cause of these features.


    • 1 January 2012
      • Vol. 63  (6) , 447-55

    Evaluation of the prevalence of metabolic obesity and normal weight among the Polish population.

    by Grażyna Bednarek-Tupikowska, Barbara Stachowska, Tomasz Miazgowski, Barbara Krzyżanowska-Świniarska, Barbara Katra, Maciej Jaworski, Justyna Kuliczkowska-Płaksej, Alicja Jokiel Rokita, Małgorzata Tupikowska, Marek Bolanowski, et al.

    In the 1980s, the idea evolved that some individuals with normal weight (Metabolically Obese, Normal-Weight), who probably have increased abdominal fat, have metabolic disturbances related to obesity. This observation initiated the concept of the metabolically obese but normal-weight syndrome (MONW). Since then, there have been only a few studies in non-obese subjects. MONW men and women should be regarded as at high risk for cardiovascular disease. A group of 854 randomly chosen non-obese men and women, 20-40 years of age, was selected from three different areas of Poland - Szczecin, Krakow and Wroclaw. All subjects were interviewed and underwent physical examination, anthropometric measurements (waist circumference, hip circumference, BMI and WHR) as well as densitometry (total body DPX, total fat, android/gynoid deposit). Serum level of fasting glucose and insulin, indices of insulin sensibility (QUICKI) and insulin resistance (HOMA, FIRI), total cholesterol, triglycerides and HDL-C were measured using commercially available kits. LDL-C level was calculated using Friedewald's formula. The total amassed fatty tissue and its android deposit was found to be significantly greater in MONW men and women. MONW women were found to exhibit increased levels of triglycerides and LDL-C but lower levels of HDL-C. In women with excess abdominal fat (EAF), fasting glucose and insulin levels, HOMA and FIRI were considerably higher, while QUICKI was lower. Triglyceride and LDL-C levels were also higher while HDL-C levels were lower. In men with EAF, increased levels of total cholesterol and LDL-C were confirmed. The occurrence of MONW is contingent upon the diagnosis criterion and increases when the criterion represents the value of HOMA - 21.76% in women and 31.42% in men. The frequency of MONW occurrence is lower when the criterion for abdominal fat content limit is used, amounting to 15.78% in women and 7.83% in men.


    • 1 June 2011
      • Vol. 82  (6) , 426-9

    Pro12Ala PPAR gamma2 gene polymorphism in women with polycystic ovary syndrome.

    by Bozena Bidzińska-Speichert, Agnieszka Lenarcik, Urszula Tworowska-Bardzińska, Ryszard Slezak, Grazyna Bednarek-Tupikowska, Andrzej Milewicz, Katarzyna Krepuła

    The pathogenesis of PCOS has not been definitively determined and includes a number of genes linked with steroidogenesis, regulation of gonadotropin secretion, actions of insulin, obesity as well as chronic inflammatory processes. Some authors indicate that PPARgamma play a role in insulin sensitivity and are probably involved in hyperandrogenism in PCOS. The aim of the study was to assess the frequency of the Pro12Ala and Pro115Gln PPARgamma2 gene polymorphisms in women with PCOS. 54 PCOS women and 51 healthy women were recruited. Genetic studies to detect Pro12Ala and Pro115Gln PPARgamma2 gene polymorphism were performed. In the whole studied group the Pro115Gln polymorphism of the PPARgamma2 gene was not found. The frequency of the Pro12Ala polymorphism was estimated at 26.47% in the controls and at 23.15% in the PCOS patients. Women from the control and PCOS groups with BMI > or = 30 had statistically higher occurrence of the Ala allele than women with BMI <30 (38.80% versus 12.50% and 38.23% versus 18.75%). The frequency of the Pro12Ala polymorphism observed in the sample of women from the Lower Silesian population was significantly higher than in the majority of European populations.


    • 1 January 2011
      • Vol. 62  (2) , 181-5

    A case of Cushing's syndrome in pregnancy.

    by Grażyna Bednarek-Tupikowska, Eliza Kubicka, Teresa Sicińska-Werner, Anna Kazimierczak, Jacek Winowski, Małgorzata Tupikowska, Maria Janczyszyn, Marek Bolanowski

    Cushing's syndrome (also known as hypercortisolemia) is rare in pregnant women due to the menstrual disturbances and infertility in women with hypercortisolism. A diagnosis of pathological hypercortisolism in pregnant women is often difficult as some symptoms of the disease may be associated with a complicated pregnancy. Hypercortisolemia leads to serious complications for mother and foetus, and is associated with premature labour and high foetal mortality. Hormonal and radiological diagnostics in pregnancy are limited. The results of hormonal measurements and dynamic tests are difficult to interpret due to the physiological changes in the hypothalamo-pituitaryadrenal axis connected with pregnancy. The optimal time and method of treatment should be chosen cautiously case by case because of the possibility of maternal and foetal complications. In this paper, we present a case of Cushing's syndrome secondary to adrenal adenoma in which the diagnosis was made in the 22(nd) week of pregnancy. Due to the advanced gestational status and mild symptoms of hypercortisolism, only symptomatic treatment was introduced. The patient was under continuous obstetric and endocrinological care. At 35 weeks of gestation, the pregnancy was terminated by emergency caesarean section because of premature detachment of the placenta. A male infant weighing 2,450 g was delivered; neither adrenal insufficiency in the child nor hypercortisolemia complications in the mother were observed.


    • 2 July 2009
      • Vol. 60  (3) , 172-9

    Lack of relationship between 174G_C promoter polymorphism of the IL-6 gene and indices of metabolic syndrome in non-obese healthy subjects.

    by Urszula Tworowska-Bardzińska, Eliza Kubicka, Ryszard Slezak, Monika Mielcarek, Grazyna Bednarek-Tupikowska, Marek Bolanowski, Andrzej Milewicz

    Homozygosity for interleukin-6 (IL-6) 174G_C promoter polymorphism has recently been associated with indices of metabolic syndrome; however, this problem has not been investigated in non-obese subjects. The aim of this study was to explore the relation between abdominal fat distribution and some inflammatory risk factors of atheromatosis and IL-6 174G_C gene polymorphism in non-obese healthy subjects. Relationships were investigated between anthropometric variables, i.e. weight, height, BMI, waist circumference (WC), waist-to-hip ratio (WHR), body fat distribution (DXA), serum CRP and IL-6, insulin sensitivity/resistance indices, and IL-6 174G_C gene polymorphism, in healthy non-obese Polish subjects: 232 women (age 31.4 +/- 5.5 years) and 199 men (age 30.3 +/- 6.0 years). The genetic study revealed that the CC genotype was observed in 15.56% of subjects, the CG genotype in 52.74%, and the GG genotype in 31.7%. IL-6 and CRP concentration did not differ among the genotypes. There were also no differences regarding BMI and WHR. The only differences among genotypes, observed only in men, were those concerning total fat (CC had higher fat content than CG and GG); the difference being statistically significant between CC and GG (p < 0.05), and gynoidal fat deposit (CC had higher gynoidal fat deposit than CG and GG); the difference being statistically significant between CC and GG (p < 0.025) and between CC and CG (p < 0.05). Biochemical parameters and insulin sensitivity did not differ among the genotypes. These data show that IL-6 174G_C polymorphism is not associated with features describing metabolic syndrome in nonobese healthy subjects.